Recently, in an elegant review study, dual SGLT1/SGLT2 inhibitors have been described as promising drugs for the treatment of cancer because SGLT1 and/or SGLT2 are overexpressed in various tumors, where they deliver glucose for euglycemic glycolysis [39]. The gene discussed is SLC5A2; the disease is cancer.